Institutional investors hold a majority ownership of CASC through the 63.75% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2017, these large investors purchased a net $1.1 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 1.3 Million shares of Cascadian Therapeutics In...
POLAR CAPITAL LLP Bought 450.0 Thousand shares of Cascadian Therapeutics In...